1 – 8 of 8
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
The serological immunogenicity of the third and fourth doses of COVID-19 vaccine in patients with inflammatory rheumatic diseases on different biologic or targeted DMARDs : a Swedish nationwide study (COVID-19-REUMA)
(
- Contribution to journal › Article
- 2023
-
Mark
Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden
(
- Contribution to journal › Article
- 2022
-
Mark
Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden
(
- Contribution to journal › Article
- 2021
-
Mark
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population : A nationwide Swedish cohort study
(
- Contribution to journal › Article
-
Mark
Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden : From infection severity to impact on care provision
(
- Contribution to journal › Article
- 2016
-
Mark
A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission.
(
- Contribution to journal › Article
- 2014
-
Mark
Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register
(
- Contribution to journal › Article
- 2012
-
Mark
Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial
(
- Contribution to journal › Article